The European Medicines Agency has granted orphan drug designation to Comanche Biopharma's CBP-4888, a novel siRNA therapeutic targeting sFlt1-mediated preterm preeclampsia, which affects approximately four in 10,000 EU pregnancies annually.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.